Market Place
Sourcing Support
Rocket Pharma Announces FDA Approval of Kresladi
28 Mar 2026 //
PHARMIWEB
Rocket Pharma to Participate in Upcoming Investor Conferences
23 Feb 2026 //
PHARMIWEB
Rocket Pharma at 44th J.P. Morgan Healthcare Conference
05 Jan 2026 //
BUSINESSWIRE
Rocket Pharma To Attend Evercore Healthcare Conference
25 Nov 2025 //
BUSINESSWIRE
Rocket Pharma Reveals Q3 2025 Financials & Recent Advances
06 Nov 2025 //
BUSINESSWIRE
Rocket Pharma Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)
10 Oct 2025 //
PHARMIWEB
Rocket Pharma`s Shares Soar After FDA Lets Therapy Trial Resume
21 Aug 2025 //
REUTERS
Rocket Trims Headcount and Focuses Pipeline Amid Turbulence
25 Jul 2025 //
BIOSPACE
Rocket Adjusts Trajectory, Laying Off Staff and Narrowing Focus
24 Jul 2025 //
FIERCE BIOTECH
FDA halts Rocket Pharma`s Gene Therapy Trial as Patient Dies
27 May 2025 //
REUTERS
Rocket Pharma Shares Ph 1 Data on RP-A601 at ASGCT 2025
15 May 2025 //
BUSINESSWIRE
Rocket Pharma Announces Data on RP-A601 at ASGCT Meeting
09 May 2025 //
BUSINESSWIRE
Rocket Pharmaceuticals at 24th Annual Needham Healthcare Conf
03 Apr 2025 //
BUSINESSWIRE
Rocket Pharma Reports Q4 & Full Year 2024 Financial Results
27 Feb 2025 //
BUSINESSWIRE
Rocket Pharma to Participate in 43rd Annual J.P. Morgan Conference
02 Jan 2025 //
BUSINESSWIRE
Rocket Pharma Announces Upsized Public Offering Pricing
11 Dec 2024 //
BUSINESSWIRE
Rocket Pharmas Announces Proposed Public Offering of Common Stock
10 Dec 2024 //
BUSINESSWIRE
Rocket Pharma to Present RP-A501 Data for Danon Disease at AHA 2024
12 Nov 2024 //
BUSINESSWIRE
Rocket Pharma at UBS Global Healthcare Conference
08 Nov 2024 //
BUSINESSWIRE
Rocket Pharma Q3 2024 Results & Recent Progress Highlights
07 Nov 2024 //
BUSINESSWIRE
Rocket Pharmaceuticals Completes Enrollment In Phase 2 Danon Disease Trial
17 Sep 2024 //
BUSINESSWIRE
Rocket Appoints Mikael Dolsten To Board Of Directors
10 Sep 2024 //
BUSINESSWIRE
Rocket Pharmaceuticals Reports Q2 2024 Results And Recent Progress
05 Aug 2024 //
BUSINESSWIRE
Rocket Gene Therapy`s Approval Delayed By FDA Rejection Over Manufacture Issues
28 Jun 2024 //
FIERCE BIOTECH
EC grants orphan medicinal product status to Rocket’s RP-A601
30 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Rocket Pharma Announces EMA Acceptance of RP-L102 MAA for the Fanconi Anemia
02 Apr 2024 //
BUSINESSWIRE
Is Rocket Pharmaceuticals Inc Stock at the Top of the Biotechnology Industry?
13 Feb 2024 //
INVESTOR OBSERVER
Rocket Announces FDA Acceptance of BLA with Priority Review for RP-L201
02 Oct 2023 //
BUSINESSWIRE
Rocket Pharma Reaches FDA Alignment on Pivotal Phase 2 Trial for RP-A501
12 Sep 2023 //
BUSINESSWIRE
Rocket Pharmaceuticals Receives EMA Priority Medicines Designation for RP-A501
31 May 2023 //
BUSINESSWIRE
Rocket Receives FDA RMAT Designation for RP-L301
23 May 2023 //
BUSINESSWIRE
Rocket`s hematology programs blast off toward regulators
19 May 2023 //
FIERCE BIOTECH
Rocket Pharma receives FDA IND clearance for ACM Phase I trial
10 May 2023 //
CLINICAL TRIALS ARENA
Rocket Pharmaceuticals Announces FDA Clearance of IND for Trial of RP-A601
09 May 2023 //
BUSINESSWIRE
Rocket Announce Leadership Expansion to Support Company Towards Commercial Stage
04 Apr 2023 //
BUSINESSWIRE
Rocket receives show of confidence in gene therapy from FDA
07 Feb 2023 //
FIERCE BIOTECH
Rocket Pharma Expands Cardiac Gene Therapy Portfolio for PKP2-ACM
09 Jan 2023 //
BUSINESSWIRE
